• Protease Inhibitor Cocktail: Practical Use

  2026-09-20

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit degradation of extracted proteins while avoiding EDTA in workflows that depend on divalent cations. It is suited to protein extraction, Western blotting, co-immunoprecipitation, pull-down, imaging, and kinase assays, but should not be treated as a universal substitute for metalloprotease inhibition or used without compatibility testing in DMSO-sensitive assays.

• LY2109761: TGF-β Signaling Workflow Guide

  2026-09-19

  LY2109761 provides a practical way to connect TGF-β receptor kinase activity with measurable Smad2/3, migration, invasion, fibrosis, and treatment-response phenotypes. This guide covers assay setup, dosing logic, radiosensitization and cancer workflows, plus troubleshooting for phospho-signaling experiments.

• Protease Inhibitor Cocktail: Preserving Assay Meaning

  2026-09-18

  A Protease Inhibitor Cocktail is more than a routine lysis additive: it protects the molecular evidence needed to interpret LRPPRC–dasatinib OXPHOS experiments. This guide explains how EDTA-free, broad-spectrum protection improves decision-making across Western blotting, Co-IP, tissue extraction, and kinase workflows.

• Protease Inhibitor Cocktail EDTA-Free: K1010

  2026-09-18

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation. It is suited to EDTA-sensitive workflows, including phosphorylation analysis and enzyme assays, but it should not be treated as a phosphatase inhibitor or as a substitute for assay-specific compatibility testing.

• VER 155008: HSP 70 Mechanism Beyond Cancer

  2026-09-17

  VER 155008 is an adenosine-derived HSP 70 inhibitor that connects chaperone biochemistry with apoptosis, cancer cell proliferation inhibition, and HSC70-dependent viral entry research. This article explains how the TGEV study can refine assay interpretation without overstating the compound’s antiviral evidence.

• Protecting DFCP1–ATGL Evidence in Lipolysis Assays

  2026-09-17

  A translational framework for preserving DFCP1–ATGL biology during lipid-droplet extraction, selecting an appropriate Protease Inhibitor Cocktail, validating EDTA compatibility, and separating genuine mechanistic signals from extraction artifacts.

• Protease Inhibitor Cocktail: Preserving TCR Biology

  2026-09-16

  The Protease Inhibitor Cocktail helps preserve native protein complexes during extraction, with particular value for LAG-3/TCR signaling studies. This article connects EDTA-free protease control to assay design, phosphorylation-sensitive workflows, and interpretation of recent T-cell checkpoint research.

• Thymoquinone: Cardiotoxicity Research Workflows

  2026-09-16

  Build reproducible doxorubicin cardiotoxicity assays with Thymoquinone by combining formulation control, cardiac function measurements, oxidative-stress profiling, and ferroptosis-relevant markers. This workflow translates a recent mouse finding into practical assay choices while clearly separating evidence-backed parameters from optimization recommendations.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-09-15

  This review synthesizes two decades of clinical experience with toremifene, a selective estrogen receptor modulator developed as an alternative to tamoxifen for hormone-sensitive breast cancer. Its main contribution is a balanced interpretation of efficacy, safety, tissue-selective activity, and pharmacokinetic differences, positioning toremifene as a potential option for selected postmenopausal patients rather than as a universally superior endocrine therapy.

• Trelagliptin and PI3K/AKT Signaling in Adipocytes

  2026-09-15

  The reference study identifies a cellular mechanism by which trelagliptin succinate may improve insulin resistance in differentiated 3T3-L1 adipocytes. Its results connect increased IRS-1/AKT signaling, GLUT4 membrane localization, and glucose uptake with reduced free fatty acid and resistin secretion, while also highlighting the limits of inferring mechanism from an in vitro model.

• Protease Inhibitor Cocktail for Plant Extracts

  2026-09-14

  Protect plant proteins from multi-class proteolysis without adding EDTA that may disrupt metal-dependent assays. This workflow shows how to use a 100X DMSO formulation for Western blots, interaction studies, kinase assays, and mechanistic research on aluminum-stress signaling.

• Protease Inhibitor Cocktail: MS-SAFE Workflow

  2026-09-14

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue extraction while avoiding AEBSF in mass spectrometry workflows. It is appropriate for proteomic and biochemical sample preservation, but it does not replace separate metalloproteinase control or establish activity within a protease signaling pathway.

• MPP7, EMT, and Polarity in Ovarian Cancer

  2026-09-13

  The reference study identifies MPP7 as an overexpressed, prognostically relevant regulator of epithelial ovarian cancer behavior. Integrated database, tissue, imaging, functional, transcriptomic, and protein analyses support a model in which MPP7 promotes polarity disruption and malignant progression through Wnt/β-catenin-associated EMT.

• L-Phenylephrine: From α1A Signaling to Translation

  2026-09-12

  L-Phenylephrine offers a focused way to investigate adrenergic α1A receptor biology across cardiovascular, neural, and vascular models. This thought-leadership guide connects receptor selectivity with sex-dependent blood-pressure regulation, experimental design, translational boundaries, and a practical validation strategy.

• Sphingosine-1-phosphate Assay Workflows

  2026-09-11

  Build controlled S1P experiments that distinguish receptor-proximal signaling from delayed apoptosis and endothelial remodeling. This workflow translates a neuronal hemorrhage study into practical dose-response, validation, and troubleshooting strategies without assuming that S1P produces the same outcome in every cell type.

8527 records 1/569 page Next 12345 下5页 Last page